Between 2000 and 2018, thirty-five of the largest pharmaceutical companies reported total revenues of nearly $12 trillion9 and profits of almost $2 trillion. They achieved these gains in part by pricing their medicines beyond reach of ordinary people. Insulins, for example, had nearly quadrupled in price10 over the previous decade, while multiple sclerosis drugs had risen more than fivefold.
